fbpx Skip to main content

Member's Profile

Harpoon Therapeutics

Location
131 Oyster Point Blvd., Ste. 300
South San Francisco,   CA
94080
United States
Sector
Biotech
Membership Info
Membership Type: Industry
Membership Since: 2016
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Harpoon Therapeutics
Biotech Company
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon’s first product, HPN424, targets PSMA and is in a Phase 1 trial for metastatic castration-resistant prostate cancer.
Related News
No related news posted by this Member